, Sctagaya-ku, Tokyo 158, lapan AMTRACX Routine carcinogenicity testings have been designed and conducted primarily for providing data to show whether or not the test compounds have a potential of inducing tumors in animals. Therefore, in the case of safety assessment or risk assessment of test compounds in humans, additional data are needed, at times, to learn how intensely the test compound can induce tumors in animals or by which mechanism the test compound can induce tumors in animals. The initiation/promotion experiment is performed as a proceeding for such requests. This paper describes the updating principle and procedures to evaluate initiation effects and promotion effects separately. However, it must be realized that our present knowledge about the initiation/promotion is still limited to some qualitative evidences. Actually, we know very little about mechanistic background and quantitative aspect of the initiation/promotion such as the site or mode of action of promoter action, the organ-specificity of promoter action, or threshold of the initiator action and promoter action. All these problems are necessary to be studied systematically in order that the initiation/promotion design can make a more important contribution to the evaluation of carcinogenicity of chemicals.
Routine carcinogenicity testings have been designed and conducted primarily for providing data to show whether or not the test compounds have a potential of inducing tumors in animals. Therefore, in the case of safety assessment or risk assessment of test compounds in humans, additional data are needed, at times, to learn how intensely the test compound can induce tumors in animals or by which mechanism the test compound can induce tumors in animals. The initiation/promotion experiment is performed as a proceeding for such requests. This paper describes the updating principle and procedures to evaluate initiation effects and promotion effects separately. However, it must be realized that our present knowledge about the initiation/promotion is still limited to some qualitative evidences. Actually, we know very little about mechanistic background and quantitative aspect of the initiation/promotion such as the site or mode of action of promoter action, the organ-specificity of promoter action, or threshold of the initiator action and promoter action. All these problems are necessary to be studied systematically in order that the initiation/promotion design can make a more important contribution to the evaluation of carcinogenicity of chemicals. I NTRO D u CTI 0 N The purpose of my presentation is to describe the scientific basis and practical methods of the initiation/promotion experiment to be conducted in carcinogenicity bioassays. Before entering into the main subject, it is desirable to mention briefly about the relationship between the carcinogenicity study and carcinogenicity testing.
The carcinogenicity study is a research work to elucidate the carcinogenic mechanism or to establish experimental models of human cancer. The cellular autonomy concept of cancer cells and the initiation/promotion concept in carcinogenesis are regarded as important products of carcinogenicity studies. On the other hand, the carcinogenicity testing is a routine task to obtain a data for classifying a test compound into either a carcinogenic sub-* Prcscntcd at thc Sccond International Symposium of thc Socicty of Toxicologic Pathologists. Scssion 111: Morphologic Considcrations in Protocol Design. May [9] [10] [11] 1983 , Arlington. Virginia. This Symposium section is continucd from Volumc 11. Number 1. 1983. stance or non-carcinogenic substance. Having different respective purposes, these 2 works are similar in methodological aspects, and their results are exchangeable each other. From the historical point of view, it is understood that the methodology as well as evaluation criteria used in the carcinogenicity testing such as the choice of animal species or strain, the selection of dose levels or dose periods and histopathological criteria of tumors have been established on the basis of evidences from carcinogenicity studies. In other words, the carcinogenicity testing can be elaborated by introduction of new concepts or evidences derived from allied carcinogenicity studies. Therefore, the present topic is said to describe why and how the initiation/promotion concept or experiment, a new product of carcinogenicity studies, is being introduced into current carcinogenicity bioassays.
Evaluation of Carcinogenicity Test Results
According to the principle proposed by IARC (I), a test compound is judged as being positive for carcinogenicity when the test re-HAYASHI TOXICOLOGIC PATHOLOGY sults turn out to meet one of the following 3 criteria; 1) a significant increase in the incidence of the same types of neoplasms as found in the control animals, 2) the occurrence of types of neoplasms not observed in control animals and 3) a decreased latent period for the production of neoplasms in comparison with that in control animals. These criteria. are still useful for the evaluation of routine carcinogenicity testings. However, it must be realized that the routine carcinogenicity testings have been designed primarily to detect or presume a weak carcinogenicity or noncarcinogenicity of test compounds, so that, theoretically, they can only provide data to show whether or not the test compounds have a potential of inducing tumors in animals. Therefore, in the case of safety assessment or risk assessment in humans, additional data are needed, at times, to learn how intensely the test compound can induce tumors in animals (2) or to which type of carcinogens the test compound belongs, namely, primary carcinogen (genotoxic carcinogen), secondary carcinogen (epigenetic carcinogen) or promoter. (3) The initiation/ promotion experiment is performed as a proceeding for such requests.
Induction of Tumor By Promoter Alone
A promoter is defined as a substance which can induce tumors when administered to animals pretreated with certain initiator (Fig. 1 ). Therefore, it is a prerequisite to promoter that the administration of a promoter alone is not associated with the induction of tumors in animals. However, provided that initiated cells have occurred in experimental animals due to the effects of either genetic factors or environmental factors such as viruses or die-Initiator @I Cancer (-) Promoter Cancer ( -) Initiator Promoter 
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FIG. 1-lnitiation/Promotion Design in Chernical Carcinogenesis
FIG. 2-Evaluation of Promoter Effect and Initiator Effect
tary contamination of carcinogens, it is theoretically possible that the administration of promoter alone results in the induction of tumors or the decreased latent period for the production of tumors. Such possibilities can be suggested in routine carcinogenicity studies when test compounds induced significantly higher incidence of tumors only in the sites where similar tumors are known to occur spontaneously. Hepatic cell tumor (4) in C3H mice or B6C3F1 mice, thymic lymphoma in AKR mice, pulmonary adenoma (5) in A mice, pheochromocytoma in SD rats and large granular lymphatic leukemia (6) in F344 rats are possible examples.
Evaluation of Promoter
The test method of promoter action consists of 3 processes, the administration of initiator, the administration of test compound and the evaluation of test results (Fig. 2 ). In some cases, partial resection of the target organs such as partial hepatectomy or partial pancreatectomy can be performed before or after the administration of initiator in order to facilitate the effect of initiator. The evaluation of test results are usually made by histopathological or histochemical examination of neoplastic lesions or preneoplastic lesions in target sites. Histometrical examination by means of the image analyzer is useful for quantifying the occurrence of such lesions (7) . The dose of initiator as well as the administration period of test compound are critical factors in the promoter bioassay because the false negative result can be caused by unsuitable setting of these 2 variables. For the final judgement of test results, it is advantageous to have run the positive control group in parallel with the groups of test compound.
Recent studies have indicated that the effects of promoters are organ-specific, (8) strictly speaking, specific to certain type of tissues or cells: TPA, teleocidin (9) and benzoyl peroxide (10) for the skin or epidermal cells; phenobarbital, PCB and DDT for the liver or hepatic cells and; sodium saccharin and tryptophan for the urinary bladder or transitional epithelium. Therefore, it is necessary for the evaluation of promoter to establish the methods specifically applicable to each kind of organs or tissues.
Assay methods for the skin and the liver have been well established. For the skin, dimethylbenz[a]anthracene is used as an initiator, and the use of Sencar mice (10) is reported to increase the sensitivity of testing. For the liver, diethylnitrosamine or N-2-fluorenylacetamide is used as initiators, and histoc hemical met hods for y-glu t am yl t ranspeptidase, adenosinetriphosphate or glucose-6phosphatase are applicable to the evaluation of test results in combination with the routine histopathological examination. Ito et al. have published a test method for the urinary bladder in rats by use of N-butyl-N-(4-hydroxybutyl)nitrosamine(BBN) as an initiator. (11) Recently, Hiasa et al. (12) and Tsuda et al. (13) have reported that the administration of phenobarbital can enhance the induction of thyroid tumors in rats initiated with N-nitrosobis(Zhydroxypropy1) amine or N-ethyl-N-hydroxyethylnitrosamine(EHEN).
On the basis of these informations along with our own data, an assay system of organspecific promoter for the liver, kidney, pancreas, skin and stomach is now being established in our institute to test various compounds including food additives, medical drugs and evironmental contaminants ( Table  1) served that feeding of the diet containing sodium chloride at a concentration of 10% can enhance the induction of adenocarcinoma of the glandular stomach in W i s h rats pretreated with N-methyl-N'-nitro-N-nitrosoguanidine. Kurokawa et al. (15) have reported that administration of potassium bromate in a drinking water at a concentration of 500 ppm is associated with high incidence of renal cell tumors in F344 rats initiated with EHEN.
In our institute, 2 models are used to evaluate the promoter effect for the pancreas; a BOP-hamster model for ductal tumors and a HAQO-rat model for acinar cell tumors. It may be worthwhile mentioning a circumstance how the HAQO-rat model was established. Fig. 3 shows the chemical structure of 4-hydroxyaminoquinoline 1-oxide(HAQ0). In 1971, it was shown that a single intravenous injection of HAQO could induce pancreatic acinar cell adenomas consistently in male rats but rarely in female rats (16) . As a mechanism of the sexual difference, it was postulated that the androgenic hormone could promote the pancreatic tumorigenesis by HAQO. Following experiments were performed to ascertain this possibility (17) .
Three male groups (group I m , 2m and 3m) and 3 female groups (group If, 2f and 3f) each consisting of 20 rats (SD) received a single i.v. injection of HAQO in a dose of 9 mg/kg (2/3 
TABLE 1-Possible Models for Evaluation of Organ-Specific Promoters
N-Butyl-N-(4-hydroxybutyl)nitrosamine Rat
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LDS0 in rats by i.v. injection). Group l m and If rats were allowed to live without further treatment. In other groups all rats were subjected to castration under Nembutal anesthesia on the 5th day, and after that, they were given weekly subcutaneous injections of either 1 mg/rat of testosterone propionate (Groups 3m and 3f) or 0.1 ml/rat of olive oil (groups 2m and 2f) from the 6th day till the termination of the experiment. As the control groups, 30 each of male and female rats received an i.v. injection of 0.2 ml of 0.0025 N HC1, and then they were allowed to live without further treatment. The experiment was terminated on the 400th day, and all rats were autopsied for histopathological examination of the pancreas.
Occurrence of pancreatic tumors of each group is shown in Table 2 . Exocrine adenomas of the pancreas did not occur in any rat of the control groups. In the groups treated with HAQO injection alone, the pancreatic tumors appeared in 8 of 12 male rats (group Im) and 1 of 11 female rats (group If). In relation to the sexual difference, it was shown that castration following HAQO administration diminished the incidence of the pancreatic tumors in male rats, and that combined treatment with castration and testosterone administration resulted in a high incidence of the pancreatic tumors in both sexes. These findings indicate that testosterone can promote the induction of the pancreatic tumors in rats by HAQO.
Evaluation of Initiator Action
It is well known that carcinogenic substances in classical sense have both initiator action and promoter action. For example, N-2-fluorenylacetamide, a potent hepatocarcinogen can promote the hepatocarcinogenesis4n rats initiated with diethylnitrosamine. Therefore, the evaluation of initiator action should be made in parallel with the test for the promoter in order to determine whether the test compound is a pure promoter or a complete carcinogen.
At present, a series of in vitro short-term tests for genotoxicity such as Ames test, chromosomal aberration test, sister chromatid exchange test and cell transformation test are used for the evaluation of initiator action. These methods are technically advantageous as routine testings, but it must be borne in mind that they can not afford the informations regarding the target organ of test compounds or the availability of test compounds to their target organ. These problems can be partly covered by .in vivo biochemical studies on the DNA-adducts or the unscheduled DNA synthesis by test compounds.
The initiator action can be evaluated by the method devised in a manner similar to that for the promoter action. As shown in Fig. 2 , the method consists of 3 processes, the administration of a test compound, the administration of a certain promoter and the evaluation of test results. In this test, it is recommendable   TABLE 2 to administer the test compound to animals at a maximum tolerant dose level or a technically permissible dose level for a period from a few weeks to several months because the administration of insufficient amount of test compound is liable to cause false negative results. Recently, Takahashi et al. (14) , using this method, tested a series of amino acid pyrolysates for the initiator action to mouse skin and showed that T r p -b , a tryptophan pyrolysate, possessed an initiator action to the mouse skin of this strain. In this experiment, they painted the dorsal skin of female ICR mice with test compounds . dissolved in dimethylsulfoxide at saturated concentrations twice a week for 5 weeks and after 3 weeks applied TPA twice a week for 40 weeks.
-Effects of Castration and Testosterone Propionate on Induction of Pancreatic Tumors in Rats by
4-Hydroxyarninoquinoline 1-Oxide
Conclusion
The initiation/promotion concept is a thesis established nearly 40 years ago by Berenblum, Mottram, Rouse and Hecker on the basis of their experimental data on skin carcinogenesis. (18) This concept is being accepted as a general principle for the carcinogenic process in experimental animals as well as in humans and now applied to the evaluation of carcinogenicity of chemicals. However, it is pointed out that our present knowledge about the initiation/promotion is limited to some qualitative and phenomenological evidences. Actually, we know very little about the mechanistic background and quantitative aspect of the initiation/promotion such as the site or mode of promoter action, the organ-specificity of the promoter action, the difference of mutagenic action and initiator action or threshold of the initiator action and promoter action. The test methods for the quantitative evaluation of the initiator action and promoter action remain undeveloped either. All these problems are necessary to be studied systematically in order that the initiation/promotion design can make a more important contribution to the evaluation of carcinogenicity of chemicals.
1.
2.
HAYASHI
TOXICOLOGIC PATHOLOGY DISCUSS~ON OF THE PAPER DR. ALDEN: I enjoyed your talk. I appreciate the contribution of initiation/promotion studies and the understanding of mechanisms in carcinogenesis. I'm in an industrial setting. What we have to do in our setting is have practical application for the tests we apply in safety testing. From what I understand, it seems like here you are suggesting that there may be a secondary level of testing in the safety assessment. My question to you then is-if you have a promoter, what do you do about it in Japan? What's the regulatory stance? As I understand it, in the United States-and I'd be interested in communication from the people that are in regulatory areas here-we don't know exactly what to do with promoters. What do you do with them in Japan? DR. HAYASHI: In Japan, initiation/promotion experiments for safety assessment have just started, actually two or three years ago. Also, it should be added that initiation/promotion experiments still remain only preliminary experiments or secondary studies for the evaluation of carcinogenicity at present. That may be the same in the United States, I think.
DR. ALDEN: Do you accept the threshold concept for promoters, or is there a safe level for promoters? Do you personally believe that?
DR. HAYASHI: I personally believe that threshold exist not only for promoters but aIso initiators, therefore, I think that the quantitative evaluation of carcinogenicity should be done by routine testing. In order to confirm or to get some implication of the routine testing, initiation/promotion studies are useful.
DR. REDDY: The presentation was excellent. Could you speculate on the mechanism of testosterone induced promotion in pancreatic acinar cell lesions? Are there receptors for testosterone or is that not so? DR. HAYASHI: Yes. In the slide I showed only the data of testosterone propionate. Actually, we used various kinds of steroids, including anabolic steroids and estrogenic steroids. We have some data on anabolic steroids with very low androgenic activity. They also promoted in pancreas so that I think that anabolic activity is related to the promotion of the induction of acinar cell tumors.
DR. REDDY: What happens with the hamster model with the desoxypropyl nitrosamine?
DR. HAYASHI: It is now underway. Some heavy metal wds shown to promote ductal cell tumors.
DR. VESSELINOVITCH: I hope so. How are you going to decide what tissue site to look at? If you go back-urethane, ethylcarbonate was originally a complete carcinogen for the lungs, then an initiator for the skin, then a promoter for slow carcinogenesis.
DR. HAYASHI: I am not famiIiar with the data you mention, so I can't answer at this time.
